SpectRx Cervical Cancer Test Trial Begins In June; Panel Review Anticipated
This article was originally published in The Gray Sheet
Executive Summary
SpectRx expects that data from a pivotal study of its non-invasive cervical cancer detection system will undergo FDA Obstetrics & Gynecology Devices Panel scrutiny after a PMA is submitted
You may also be interested in...
MediSpectra Luma Cervical Imaging System Granted Expedited Review
MediSpectra hopes itsLuma cervical imaging system PMA will be reviewed by FDA's Obstetrics & Gynecological Devices panel this fall and approved in early 2005
MediSpectra Luma Cervical Imaging System Granted Expedited Review
MediSpectra hopes itsLuma cervical imaging system PMA will be reviewed by FDA's Obstetrics & Gynecological Devices panel this fall and approved in early 2005
SpectRx’ Double Play: Extend SimpleChoice Line, Ink Glucose Monitor Partner
SpectRx could be cash-flow neutral in 2005 if SimpleChoice diabetes management product line sales increase as expected, CFO Thomas Muller predicted during a March 31 earnings call